Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines

International Journal of Cancer

Volumn 103, Issue 5, 2003, Pages 587-599

  Liani, Esti ^a   Rothem, Lilah ^a   Bunni, Marlene A ^b   Smith, Clyde A ^c   Jansen, Gerrit ^d   Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifolates; Drug resistance; Mutations; Polyglutamylation

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; AG 377; AMINOPTERIN; DIHYDROFOLATE REDUCTASE INHIBITOR; EDATREXATE; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; LOMETREXOL; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; TRIMETREXATE GLUCURONATE; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL ISOLATION; CELL TRANSPORT; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG MECHANISM; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE MUTATION; GENE STRUCTURE; HUMAN; HUMAN CELL; HYDROPHILICITY; LACTOBACILLUS CASEI; LEUKEMIA; LEUKEMIA CELL; LIPID SOLUBILITY; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

BASE SEQUENCE; BINDING SITES; BIOLOGICAL TRANSPORT; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIVISION; DNA PRIMERS; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FOLIC ACID; FOLIC ACID ANTAGONISTS; GENES, DOMINANT; HUMANS; LEUKEMIA; MUTATION; PEPTIDE SYNTHASES; POLYGLUTAMIC ACID; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0037455808     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10829     Document Type: Article

References (72)

1. Stockstad ELR. Historical perspective on key advances in the biochemistry and physiology of folates. In: Piccianno MF, Stockstad ELR, Gregory JF, eds. Folic acid metabolism in health and disease. New York: Wiley-Liss, 1990. 1-21.
2. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948;238: 787-93.
3. Bertino JR. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
4. Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 1968;243:5007-17.
5. Jansen G, Pieters R. The role of impaired transport in (pre)clinical resistance to methotrexate-insights on new antifolates. Drug Resist Updat 1998;1:211-8.
6. McGuire JJ, Hsieh P, Coward JK, Bertino JR. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 1980;255:5776-88.
7. Habeck LL, Mendelsohn LG, Shih C, Taylor EC, Colman PD, Gossett LS, Leitner TA, Schultz RM, Andis SL, Moran RG. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazaterahydrofolate analogs. Mol Pharmacol 1995;48:326-33.
8. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-6.
9. Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cancer cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987;262:13520-6.
10. Lin B-F, Syu Huang R-F, Shane B. Regulation of folate and onecarbon metabolism in mammalian cells. Role of mitochondrial folylpoly-γ-glutamate synthetase. J Biol Chem 1993;268:21674-9.
11. McGuire JJ, Russell CA, Balinska M. Human cytosolic and mitochondrial folylpolyglutamate synthetase are electrophoretically distinct. J Biol Chem 2000;275:13012-6.
12. Lin B-F, Shane B. Expression of Escherichia coli folylpolyglutamate synthetase in the Chinese hamster ovary cell mitochondrion. J Biol Chem 1993;269:9705-13.
13. Lowe KE, Osborne CB, Lin BF, Kim JS, Hsu JC, Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-γ-glutamate synthetase substrate specificity of metabolic cycles of one-carbon metabolism. J Biol Chem 1993;268:21665-73.
14. Osborne CB, Lowe KE, Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. I. Folate metabolism in Chinese hamster ovary cells expressing Escherichia coli or human folylpolyγ-glutamate synthetase activity. J Biol Chem 1993;268:21657-64.
15. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978;253:1357-70.
16. Jackson RC, Niethammer D. Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofolate reductase. Eur J Cancer 1977;13:567-75.
17. Haber D, Beverly SM, Keily ML, Schimke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem 1981;256:9501-10.
18. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981;41:4447-52.
19. Schuetz JD, Matherly LH, Westin EH, Goldman ID. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line. J Biol Chem 1988;263:9840-7.
20. Brigle KE, Spinella MJ, Sierra EE, Goldman ID. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 1995;270:22974-9.
21. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni MA., Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ, Assaraf, YG. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98.
22. Wong S, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999;274:10388-94.
23. Drori S, Jansen G, Mauritz R, Peters G, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000; 275:30855-63.
24. Hooijberg JH, Broxterman JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
25. Kool M, van der LM, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-9.
26. Cowan KH, Jolivet JA. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem 1984;259:10793-800.
27. Pizzorno G, Mini E, Coronello M, McGuire JJ, Moroson BA, Cashmore AR, Dreyer RN, Lin JT, Mazzei T, Periti P. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988;48:2149-55.
28. McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, Mini E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia cell lines. J Biol Chem 1991;266:6181-7.
29. Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002;63: 105-15.
30. Sanghani SP, Sanghani PC, Moran RC. Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-γ-glutamate synthetase by site-directed mutagenesis. J Biol Chem 1999;274:27018-27.
31. Zhao R, Titus S, Gao F, Moran RG, Goldman ID. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606.
32. Assaraf YG, Goldman ID. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 1997;272:17460-6.
33. Jansen G, Barr HM, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9.
34. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch PA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48:459-71.
35. Jackman AL, Judson IR. The new generation of thymidylate synthase inhibitors in clinical study. Exp Opin Invest New Drugs 1996;5:719-36.
36. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates-Exploitation for folate-based chemotherapy and immunotherapy. In: Jackman AL, ed. Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press, 1999. 293-321.
37. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995;6:871-81.
38. Mendelsohn LG, Shih C, Schultz RM, Worzalla JF. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. New Drugs 1996;14:287-94.
39. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23.
40. Boritzki TJ, Barlett CA, Zhang C, Howland EF, Margosiak SA, Palmer CL, Romines WH, Jackson RC. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 1996;14:295-303.
41. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson JR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579-86.
42. Cocconi G, Cunningham D, Van Custem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM. Open, randomized, multicenter trial of ZD1694 versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16:2943-52.
43. Hanlon MH, Ferone R. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res 1996;56:3301-6.
44. Smith GK, Bigley JW, Dev IK, Duch DS, Ferone R, Pendergast W. GW1843: a potent, noncompetitive thymidylate synthase inhibitorPreclinical and preliminary clinical studies. In: Jackman AL, ed. Antifolate drugs in cancer therapy. Totowa NJ, Humana Press, Inc., 1999. 203-27.
45. O'Dwyer, PJ, Nelson K, Thornton DE. Overview of phase II trials of MTA in solid tumors. Semin Oncol 1999; 26: 82-88.
46. Hughes LR, Stephens TC, Boyle FT, Jackman AL. Raltitrexed (Tomudex), a highly polyglutamatable antifolate thymidylate synthase inhibitor. In: Jackman AL, ed. Antifolate drugs in cancer therapy. Totowa, NJ: Human Press Inc., 1999. 147-165.
47. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331-a watersoluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997;3:911-21.
48. Rhee MS, Galivan J, Wright JE, Rosowsky A. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 1994;45:783-91.
49. Wright JE, Vaidya CM, Chen Y, Rosowsky A. Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(α)-4-amino-4-deoxypteroyl)-N(δ)hemiphtaloyl-L-ornithine (PT523) and its B-ring analogues. Biochem Pharmacol 2000;60:41-6.
50. Beardsley GP, Moroson BA, Taylor EC, Moran RG. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 1989;264:328-33.
51. Jansen G, Kathmann I, Rademaker BC, Braakhuis BJM, Westerhof GR, Rijksen G, Schornagel JH. Expression of a folate binding protein in L1210 cells grown in low folate medium. Cancer Res 1989;49: 1959-63.
52. Santi DV, McHenry CS, Perriard ER. A filter assay for thymidylate synthetase using 5-fluoro-2′-deoxyuridylate as an active site titrant. Biochemistry 1974;13:467-70.
53. Schmitz JC, Grindey GB, Schultz RM, Priest DG. Impact of dietary folic acid on reduced folates in mouse plasma and tissues: relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol 1994;48: 319-25.
54. Jansen G, Schornagel JH, Kathmann I, Westerhof GR, Hordijk GJ, Van der Laan, BFAM. Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res 1992;4: 299-305.
55. Bradford MM. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
56. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1984;132:6-13.
57. Garrow TA, Admon A, Shane B. Expression cloning of a human cDNA encoding folyl(gamma-polyglutamate) synthetase and determination of its primary structure. Proc Natl Acad Sci USA 1992;89: 9151-55.
58. Sun X, Bognar AL, Baker EN, Smith CA. Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. Proc Natl Acad Sci USA 1998;95:6647-52.
59. Sun X, Cross JA, Bognar AL, Baker EN, Smith CA. Folate-binding triggers the activation of folylpolyglutamate synthetase. J Mol Biol 2001;310:1067-78.
60. Roussel A, Cambillau C, Turbo-Frodo. In: Silicon Graphics Geometry Partners Directory, vol. 86. Mountain View, CA: Silicon Graphics, 1991.
61. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cell lines. Biochem J 2002;367:741-50.
62. Jackman AL, Kelland LR, Kimbell LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A, Boyle FT. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 1995;71:914-24.
63. Lu K, Yin MB, McGuire JJ, Bonmassar E, Rustum YM. Mechanisms of resistance to N-[5-]N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl) -N-methylamino]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem Pharmacol 1995;50:391-8.
64. Takemura Y, Kobayashi H, Gibson W, Kimbell R, Miyachi H, Jackman AL. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukemia cells. Int. J. Cancer 1996;66:29-36.
65. Freemantle SJ, Jackman AL, Kelland LR, Calvert AH. Molecular characterization of two cell lines selected for resistance to the folatebased thymidylate synthase inhibitor, ZD1694. Br J Cancer 1995;71: 925-30.
66. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26:68-73.
67. Mauritz R, Bekkenk MW, Rots MG, Pieters R, Mini E, Van Zantwijk CH, Veerman AJP, Peters GJ, Jansen GJ. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 1998;4:2399-410.
68. Roy K, Egan MG, Sirlin S, Sirotnak FM. Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell: Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. J Biol Chem 1997;272:6903-8.
69. Chen L, Qi H, Korenberg J, Garrow TA, Choi YT, Shane B. Purification and properties of human cytosolic folylpoly-γ-glutamate synthetase and organization, localization and differential splicing of its gene. J Biol Chem 1996;271:13077-87.
70. Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, Edelmann W, Goldman ID. Rescue of embryonic lethality in reduced folate carrierdeficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 2001;276: 10224-8.
71. Zhao R, Sharina IG, Goldman ID. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol 1999;56: 68-76.
72. Assaraf YG, Babani S, Goldman ID. Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells. J Biol Chem 1998;273:8106-11.